- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 849-863 of
973 results
1074 Exhibit: WO098
Document
IPR2023-00724, No. 1074 Exhibit - WO098 (P.T.A.B. Mar. 16, 2023)
|
|
Cite Document
1112 Exhibit: Exhibit 1112 Ostawal
Document
IPR2023-00724, No. 1112 Exhibit - Exhibit 1112 Ostawal (P.T.A.B. May. 22, 2024)
|
|
Cite Document
2520 Exhibit: EX2520 NYU Langone Health, “Medication for Type 2 Diabetes,” https...
Document
IPR2023-00724, No. 2520 Exhibit - EX2520 NYU Langone Health, “Medication for Type 2 Diabetes,” httpsnyulangoneorgconditionstype 2 diabetestreatmentsmedication for type 2 diabetes (P.T...
|
|
Cite Document
2604 Exhibit: EX2604 V Perkovic et al, Effects of Semaglutide on Chronic Kidney D...
Document
IPR2023-00724, No. 2604 Exhibit - EX2604 V Perkovic et al, Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes, N Engl J Med May 24, 2024 Marked As Exhibit 1...
|
|
Cite Document
2067 Exhibit: EX2067 Evaluation and Licensing Division, Pharmaceutical and Food...
Document
IPR2023-00724, No. 2067 Exhibit - EX2067 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, “Report on the Deliberation Res...
|
|
Cite Document
2484 Exhibit: EX2484 IMS Institute for Healthcare Informatics, Price Declines after...
Document
IPR2023-00724, No. 2484 Exhibit - EX2484 IMS Institute for Healthcare Informatics, Price Declines after Branded Medicines Lose Exclusivity in the US Jan 2016, available at httpswwwiqviacom...
|
|
Cite Document
2069 Exhibit: EX2069 Ozempic® Prescribing Information September 2023
Document
IPR2023-00724, No. 2069 Exhibit - EX2069 Ozempic® Prescribing Information September 2023 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2510 Exhibit: EX2510 Novo Nordisk, Financial report for the period 1 January 2022...
Document
IPR2023-00724, No. 2510 Exhibit - EX2510 Novo Nordisk, Financial report for the period 1 January 2022 to 31 March 2022 Apr 29, 2022 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2108 Exhibit: EX2108 Reiter Brennan, C, Comprehensive Care Models for Cardiom...
Document
IPR2023-00724, No. 2108 Exhibit - EX2108 Reiter Brennan, C, Comprehensive Care Models for Cardiometabolic Disease, Curr Cardiol Rep, 23322 2021 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2399 Exhibit: EX2399 US Food Drug Administration, DrugsFDA, Januvia®
Document
IPR2023-00724, No. 2399 Exhibit - EX2399 US Food Drug Administration, DrugsFDA, Januvia® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2369 Exhibit: EX2369 Tomkin, GH, Treatment of type 2 diabetes, lifestyle, GLP1 ag...
Document
IPR2023-00724, No. 2369 Exhibit - EX2369 Tomkin, GH, Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors, World J Diabetes, 2014 Oct 15 55636 650 (P.T.A.B. Jan. 17...
|
|
Cite Document
2449 Exhibit: EX2449 US Food Drug Administration, DrugsFDA, Xigduo® XR
Document
IPR2023-00724, No. 2449 Exhibit - EX2449 US Food Drug Administration, DrugsFDA, Xigduo® XR (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2085 Exhibit: EX2085 A Ahmann et al, “Efficacy and Safety of Once Weekly Semag...
Document
IPR2023-00724, No. 2085 Exhibit - EX2085 A Ahmann et al, “Efficacy and Safety of Once Weekly Semaglutide Versus Exenatide ER in Subjects with Type 2 Diabetes SUSTAIN 3 A 56 Week, Op...
|
|
Cite Document
2065 Exhibit: EX2065 Novo Nordisk, “Annual Report 2010” February 1, 2011
Document
IPR2023-00724, No. 2065 Exhibit - EX2065 Novo Nordisk, “Annual Report 2010” February 1, 2011 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
1137 Exhibit: Exhibit 1137 Bhansali
Document
IPR2023-00724, No. 1137 Exhibit - Exhibit 1137 Bhansali (P.T.A.B. May. 22, 2024)
|
|
Cite Document
